Continuous Bioprocessing Market Report

Furthermore, the US with USD 99.7million market in 2024, held a largest share in the global continuous bioprocessing market

• Cytiva (US) accelerates bioprocessing supply, supported by an investment of $1.6 billion since 2019 toward projects intended to satisfy the growing demand of customer. The expansion is to improve capacity and lead times for biopharmaceutical customers, supporting rapid drug development and manufacturing. (June 12, 2025)
• Thermo Fisher Scientific Inc. (US) has acquired Solventum’s purification & filtration business for approximately $4.1 billion in cash. This strategic move expands Thermo Fisher’s portfolio of single-use technologies for biopharmaceutical manufacturing, enhancing its capabilities in critical purification and filtration solutions. (February 25,2025)
• Sartorius AG (Germany) partnered with Sanofi A (France) to develop an innovative end-to-end platform for integrated and continuous downstream bioprocessing. This partnership aims to revolutionize biomanufacturing by combining Sartorius’ engineering and manufacturing expertise with Sanofi’s cutting-edge prototypes. (May 14,2024)
• Merck KGaA (Germany) signs MoU with Mycenax Biotech Inc (Taiwan) (to optimize bioprocessing production of life-changing biological therapies. The agreement includes the integration of Merck’s Bio Continuum™ platform in the entire bioprocessing spectrum for Mycenax’s customers, followed by automation and digitalization of processes. (January 24,2024)

Drivers:  Increasing Adoption of Continuous Bioprocessing among CDMOs and CMOs Drive Market Growth

The growth in adoption among pharmaceutical CDMOs and CMOs is primarily driven by the increasing trend of pharmaceutical companies outsourcing complex manufacturing processes to the specialized service providers, who are subsequently pressured to embrace advanced technologies in order to stay ahead and achieve client requirements for speed, quality, and cost-reduction. The prime driver for this development is the requirement for CDMOs and CMOs to enhance their products by adopting innovative solutions such as continuous bioprocessing and modular facilities, which enable them to service a broader range of projects more efficiently and flexibly. This broad-based adoption benefits the market as a whole by speeding up the development and certification of new manufacturing technology, setting standards, and ultimately developing a more robust and scalable global supply chain that can react faster to the emergence of new therapies.

Opportunities: Optimization Of Continuous Bioprocessing Through Process Analytical Technology (PAT)

Optimization of continuous bioprocessing using Process Analytical Technology (PAT) is motivated by the requirement for real-time monitoring and control to provide consistent product quality and efficient operation in a seamless, uninterrupted manufacturing process. This provides a huge potential to improve process understanding, eliminate variability, eliminate waste, and accelerate market entry for biopharmaceutical products. The industry is enhanced with a more accurate, data-centric manufacturing strategy that reduces cost, increases yield, and enhances regulatory compliance, making advanced biomanufacturing more scalable and accessible. One of the major market trends is that PAT is the essential facilitator for continuous bioprocessing and turns it from a theoretical principle into a commercially practicable approach, which is driving industry wide implementation and innovation in drug development and manufacturing.

Challenges: Operational Challenges Limits Continuous Bioprocessing Market

Operational issues in continuous bioprocessing (CB) arise from its inherent requirement for constant, real-time regulation of interconnected unit operations, were even slight variations in process parameters like pH, temperature, or feed consistency can snowball into critical failures. This complexity demands advanced Process Analytical Technology (PAT) and highly trained personnel for monitoring, making it more expensive and requiring heavier training loads. For the industry, these problems slow down product launch, increase manufacturing costs through troubleshooting and possible product loss, and increase regulatory oversight in case consistency of quality is compromised. Disadvantages include higher initial investments in automation and infrastructure, susceptibility to single-point failures that shut down entire production lines, and decreased industry-wide adoption with lengthy efficiency gains, eventually capping scalability and accessibility for smaller players.

The global continuous bioprocessing market, encompassing integrated upstream and downstream technologies for the seamless production of complex medicines, is set for strong growth, driven by the pharmaceutical industry’s transition from traditional batch to continuous manufacturing models. The market was valued at approximately USD 264 million in 2024, is projected to surge to over USD 861 million by 2030, achieving a significant Compound Annual Growth Rate (CAGR) exceeding 21.8 %. The growth is fueled by key drivers such as advancements in automation, single-use systems, and real-time process analytics, alongside strong regulatory support from agencies like the FDA and EMA through initiatives promoting Quality by Design and flexible manufacturing. North America holds the largest market share in 2024, attributed to its mature biopharmaceutical sector, substantial R&D investments, and a favorable regulatory climate encouraging innovation, while the Asia-Pacific region is emerging as a high-growth area due to increasing biomanufacturing capabilities, cost efficiency imperatives, and rising demand for biologics in major economies like China and India. Future market expansion will be further accelerated by the adoption of continuous processing for complex therapies like cell and gene therapies, increasing regulatory harmonization, and the critical need for more agile and resilient biomanufacturing supply chains.